Sublocade Withdrawal From Australia Shows How US Drug Pricing Policy Reverberates Globally

The pharmaceutical company Indivior announced it will withdraw Sublocade—a long-acting injectable form of buprenorphine used to treat opioid dependence—from the Australian market by December 31, 2026. The decision, described by the company as a "commercial" one, has sent shockwaves through Australia's addiction medicine community and illustrates how shifts in American pharmaceutical policy can destabilize treatment access thousands of miles away.

Sublocade represented a significant advancement when it entered Australia's Pharmaceutical Benefits Scheme in 2020. Unlike daily methadone or sublingual buprenorphine, which require frequent pharmacy visits, Sublocade is administered as a monthly injection. For patients in rural areas, those with transportation challenges, or individuals whose work schedules conflict with pharmacy hours, this formulation removed substantial barriers to consistent treatment.

"It, quite honestly, has been life-saving and life-changing for many of my patients," said Dr. Owen Harris, a Melbourne general practitioner who prescribes the medication. "Some people can stretch their dose out to once every six weeks, or even longer." Pharmacist Angelo Pricolo, who administered Australia's first Buvidal injection in 2020, noted that while an alternative monthly injection remains available, the two formulations are not interchangeable for all patients. "We sometimes see those requiring higher doses do better with Sublocade," he explained. "Choice for the patient and healthcare provider is very important and can be the factor that determines engagement in treatment or indeed a return to drug use."

The Trump Administration Connection

The withdrawal comes less than a month after AstraZeneca pulled another medication, Zoladex, from Australia citing similar commercial concerns. Both decisions reflect growing uncertainty among pharmaceutical manufacturers about how to price medications in smaller markets following the Trump administration's embrace of a "most favoured nations" approach to drug pricing.

Under this policy framework, the United States would pay the same price for medications as "reference countries"—typically smaller nations like Australia that have negotiated substantial discounts through centralized purchasing schemes. President Trump has argued that American patients subsidize lower prices abroad, with pharmaceutical companies discounting drugs to gain access to foreign markets while charging premium prices domestically.

Australian Health Minister Mark Butler acknowledged last month that "drugs pricing is in an enormous state of flux amid US policy changes." The concern among pharmaceutical executives is straightforward: if accepting lower prices in Australia forces equivalent reductions in the far larger American market, companies may find it more profitable to withdraw from smaller countries entirely rather than compromise their US revenue.

Brendan Shaw, an adjunct professor at the University of Sydney's pharmacy school and former chief executive of Medicines Australia, described the current environment as one of "chaos across the industry." Companies, he said, are "scrambling" to reassess their global pricing strategies with "one eye on what impact that's going to have on some of the major markets internationally."

Implications for Addiction Treatment

The loss of Sublocade in Australia arrives at a moment when the nation, like the United States, is grappling with sustained increases in opioid-related harms. On a single snapshot day in 2025, nearly 58,000 Australians were receiving pharmacotherapy for opioid dependence, according to data from the Australian Institute of Health and Welfare. While this represents only a fraction of the estimated population with opioid use disorder, it indicates substantial reliance on medication-assisted treatment as a cornerstone of public health response.

The withdrawal also highlights a vulnerability in treatment systems that depend on a limited number of pharmaceutical options. As Pricolo noted, "If we only have one drug and for some unforeseeable reason it cannot be accessed, then that is a huge issue. The addiction treatment space is a delicate ecosystem with an already vulnerable cohort now seemingly dealt another unfair result."

This fragility is not unique to Australia. In the United States, extended-release buprenorphine formulations have been credited with improving retention in treatment, particularly for patients who struggle with the daily discipline required by sublingual tablets or the clinic-based structure of methadone programs. The X-waiver elimination and expanded telehealth flexibilities have increased access to buprenorphine prescribing, but these policy gains depend on the continued availability of diverse formulations suited to different patient needs.

Global Ripple Effects

The Australian situation illustrates how pharmaceutical policy decisions made in Washington can reshape treatment landscapes worldwide. Critics of the "most favoured nations" approach warned that rather than lowering American prices, the policy might simply raise prices elsewhere—or eliminate access entirely—as companies withdraw from markets where price concessions could trigger US parity requirements.

For addiction medicine specifically, this dynamic creates particular concern. Unlike medications for chronic conditions where multiple therapeutic alternatives often exist, the pharmacological toolkit for opioid use disorder remains relatively narrow. Methadone, buprenorphine, and naltrexone constitute the primary FDA-approved options, with extended-release formulations representing important refinements that address adherence challenges.

The Australian federal health department, responding to the Sublocade withdrawal, emphasized that "maintaining access to safe, effective and affordable medicines remains a priority" while acknowledging that "these are commercial decisions made by private companies, and the Australian government cannot compel a company to continue supply."

Looking Forward

Indivior has stated it intends "to work with the appropriate authorities and experts in Australia to ensure an orderly transition that minimises disruption." For patients currently stabilized on Sublocade, this will likely mean transitioning to alternative formulations—either monthly Buvidal injections or daily buprenorphine preparations—before the year-end deadline.

Whether additional medication withdrawals follow will depend on how the Trump administration implements its pricing policies and how pharmaceutical companies respond. Shaw suspects more drugs may be pulled from Australia as "pressures that are building internationally" force companies to make difficult commercial decisions.

For the global addiction treatment community, the episode serves as a reminder that access to evidence-based care depends not only on clinical guidelines and healthcare infrastructure, but on the complex economics of pharmaceutical markets—and on policy decisions made in the world's largest drug market that ripple outward to affect patients everywhere.